BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38315795)

  • 1. Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis.
    Leonhardt CS; Hank T; Pils D; Gustorff C; Sahora K; Schindl M; Verbeke CS; Strobel O; Klaiber U
    Int J Surg; 2024 Jan; 110(1):453-463. PubMed ID: 38315795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
    Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
    Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis.
    Daamen LA; van Goor IWJM; Schouten TJ; Dorland G; van Roessel SR; Besselink MG; Bonsing BA; Bosscha K; Brosens LAA; Busch OR; van Dam RM; Fariña Sarasqueta A; Festen S; Groot Koerkamp B; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; de Meijer VE; Nieuwenhuijs VB; Raicu GM; Roos D; Schreinemakers JMJ; Stommel MWJ; van Velthuysen MF; Verheij J; Verkooijen HM; van Santvoort HC; Molenaar IQ;
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):708-716. PubMed ID: 33323293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma.
    Crippa S; Giannone F; Schiavo Lena M; Belfiori G; Partelli S; Tamburrino D; Delpini R; Pagnanelli M; Pecorelli N; Balzano G; Doglioni C; Falconi M
    Ann Surg Oncol; 2021 Aug; 28(8):4602-4612. PubMed ID: 33393031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
    Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
    Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of additional therapy for residual pancreatic cancer.
    Yamada S; Sonohara F; Tashiro M; Murotani K; Takami H; Hayashi M; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujii T; Kodera Y
    Surg Today; 2020 May; 50(5):440-448. PubMed ID: 31650262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    Am Surg; 2022 Jun; 88(6):1172-1180. PubMed ID: 33522271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer.
    Klaiber U; Schnaidt ES; Hinz U; Gaida MM; Heger U; Hank T; Strobel O; Neoptolemos JP; Mihaljevic AL; Büchler MW; Hackert T
    Ann Surg; 2021 Jan; 273(1):154-162. PubMed ID: 30921051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study.
    Delpero JR; Jeune F; Bachellier P; Regenet N; Le Treut YP; Paye F; Carrere N; Sauvanet A; Adham M; Autret A; Poizat F; Turrini O; Boher JM
    Ann Surg; 2017 Nov; 266(5):787-796. PubMed ID: 28953554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
    Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
    PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment.
    Leonhardt CS; Pils D; Qadan M; Jomrich G; Assawasirisin C; Klaiber U; Sahora K; Warshaw AL; Ferrone CR; Schindl M; Lillemoe KD; Strobel O; Fernández-Del Castillo C; Hank T
    Ann Surg; 2024 Feb; 279(2):314-322. PubMed ID: 37042245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
    Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
    JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective assessment of resection margin status following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma after standardisation of margin definitions.
    Pine JK; Haugk B; Robinson SM; Darne A; Wilson C; Sen G; French JJ; White SA; Manas DM; Charnley RM
    Pancreatology; 2020 Apr; 20(3):537-544. PubMed ID: 31996296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.
    Hank T; Hinz U; Tarantino I; Kaiser J; Niesen W; Bergmann F; Hackert T; Büchler MW; Strobel O
    Br J Surg; 2018 Aug; 105(9):1171-1181. PubMed ID: 29738626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma.
    Jamiyan T; Shiraki T; Kurata Y; Ichinose M; Kubota K; Imai Y
    World J Surg Oncol; 2020 Jun; 18(1):137. PubMed ID: 32571348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis.
    Leonhardt CS; Niesen W; Kalkum E; Klotz R; Hank T; Büchler MW; Strobel O; Probst P
    BJS Open; 2022 Mar; 6(2):. PubMed ID: 35301513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy.
    Depypere L; Moons J; Lerut T; De Hertogh G; Peters C; Sagaert X; Coosemans W; Van Veer H; Nafteux P
    Dis Esophagus; 2018 Feb; 31(2):. PubMed ID: 29036407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis.
    Yang B; Chen K; Liu W; Long D; Wang Y; Liu X; Ma Y; Tian X; Yang Y
    Clin Exp Med; 2023 Nov; 23(7):3159-3169. PubMed ID: 37310659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.